How an experimental drug reverses fatty liver disease

A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyc

Related Keywords

Dallas ,Texas ,United States ,Arun Radhakrishnan ,Simeng Wang ,C Vincent Prothro ,Michael Brown ,Paulj Thomas ,Wa Monty Moncrief ,Jonathan Cohen ,Scott Grundy ,Shunxing Rong ,Ajay Horton ,Philip Obryan Montgomery ,Helen Hobbs ,Jeffrey Mcdonald ,Joseph Goldstein ,Shili Li ,Louisa Beecherl Jr ,National Institutes Of Health ,Research Scientist ,Biomedical Research ,Division Of Digestive ,Welch Foundation ,Human Nutrition Research ,Arteriosclerosis Research ,Nutrition Obesity Research Center ,Cardiology Research ,Ut Southwestern Medical Center ,Leducq Foundation ,Medical Center ,Cell Metabolism ,Internal Medicine ,Liver Diseases ,Human Nutrition ,National Institutes ,Drug Administration Approved ,Dallas Heart Study ,Goncalo Dias ,Chai Wan Kim ,Assistant Professors ,Molecular Genetics ,Clinical Fellow ,Regental Professor ,Moncrief Distinguished Chair ,Prothro Distinguished Chair ,Distinguished Chair ,Philipo Bryan Montgomery ,Developmental Biology ,Eugene Mcdermott Distinguished Chair ,Human Growth ,Heart Ball Chair ,Distinguished University Chair ,Human Nutrition Director ,Endowed Chair ,Scott Grundy Director ,